Retatrutide and Tesamorelin Stack: What's Known and What Isn't

Nobody has tested retatrutide and tesamorelin together in a trial, so there's no known safe way to combine them, and the case for the stack rests on each drug's separate results. They work on different systems: retatrutide mimics three gut and pancreas hormones (GIP, GLP-1 and glucagon), while tesamorelin tells your pituitary gland to release more growth hormone. The overlap that matters is in their side effects and warnings, and the biggest one is blood sugar, which the two push in opposite directions. If you're also weighing MOTS-c as a third peptide, that's covered in retatrutide and MOTS-c.

"Reta and tesa" comes up often in peptide forums, usually with a theory about how the two complement each other. Each drug's own trials and label say more than the theory does.

What reta and tesa are

Retatrutide is Eli Lilly's once-weekly injection that activates the GIP, GLP-1 and glucagon receptors. Six Phase 3 trials have reported positive results, and TRIUMPH-1 is published in the New England Journal of Medicine, but no approved version exists yet. Lilly says "no one can legally sell it for human use." Tesamorelin is an older, approved drug: a lab-made version of growth hormone-releasing hormone (GHRH), approved in the US since 2010 under the Egrifta name and sold today as Egrifta SV and Egrifta WR. Its only approved use is reducing excess belly fat in adults with HIV who have lipodystrophy, a shift in where the body stores fat that can pile up deep in the belly.

On filing: Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

The table puts the two side by side. Every tesamorelin figure comes from the Egrifta prescribing information unless noted.

That half-life gap changes the routine. Retatrutide sits in your body all week (more in our half-life guide). Tesamorelin is mostly gone within an hour of each shot, working through the growth hormone pulse it triggers, and its label calls for an injection every day. Put together, that's 8 shots a week.

Has anyone tested retatrutide and tesamorelin together?

No. As of October 31, 2026, ClinicalTrials.gov lists 33 studies with retatrutide as an intervention and 24 with tesamorelin, and none includes both. None of the 24 tesamorelin studies gives it alongside a GLP-1 drug as a study treatment either (one diabetic eye study allowed people already on a GLP-1 drug plus insulin), so there's no class evidence to borrow from semaglutide or tirzepatide.

The labels don't settle it. The Egrifta interaction section names only drugs broken down by liver enzymes (CYP450) and steroid replacement, and retatrutide has no label because no approved version exists. Nobody has studied a direct interaction between the two, so what you can actually check are the overlapping effects in the next sections.

Why people add tesa to reta

The usual pitch has two parts: lose the deep belly fat around the organs faster, and hold on to muscle while the scale drops. Both trace back to real tesamorelin data, and the fat half looks smaller once you set it next to retatrutide's own numbers.

On belly and liver fat, retatrutide already does a lot on its own (our retatrutide belly fat page has the scan data, and fatty liver covers the liver trials). In the Phase 2 liver substudy published in Nature Medicine, 98 people with fatty liver had their liver fat measured by MRI, and it fell by more than 80% on the two top doses within 24 weeks.

Tesamorelin's best liver result came from a 12-month trial in 61 people with HIV and fatty liver, reported in The Lancet HIV in 2019: tesamorelin cut liver fat by 37% from baseline compared with placebo, and 35% of people reached normal liver fat against 4% on placebo. Outside HIV, the belly fat evidence is one trial. In 60 adults with abdominal obesity and low growth hormone, 12 months of tesamorelin cut visceral fat by 16 cm² while it rose 19 cm² on placebo (Journal of Clinical Endocrinology and Metabolism, 2012).

Muscle is the other half of the pitch, and retatrutide muscle loss covers what retatrutide scans show. In the first Egrifta trial (Study 1), lean body mass rose 1.3 kg on tesamorelin while it fell 0.2 kg on placebo over 26 weeks. Those people weren't losing weight, though, and no study has measured tesamorelin's effect on muscle during GLP-1 weight loss.

Our read: retatrutide's Phase 2 number (a drop from each person's own baseline, 24 weeks) and tesamorelin's (a difference against placebo, 12 months) are different measures in different people, so they can't be ranked, but nothing here says tesamorelin adds liver benefit on top of retatrutide. The open question a stack could answer is muscle, and nobody has run that study.

Where the side effects and warnings overlap

Each drug's risks are documented, so this is the part of a reta and tesa stack with real evidence. Retatrutide figures come from its trials; where it has none, the table uses tirzepatide or semaglutide labels, marked as class evidence.

Blood sugar deserves the most thought. The Egrifta label warns about glucose intolerance and tells doctors to check glucose before and during treatment. Later trials were calmer: a 12-week trial in 53 people with type 2 diabetes found no change in glucose control (PLOS ONE, 2017), and the HIV liver trial and the obesity trial found no difference in HbA1c. Retatrutide lowers A1C a lot in its trials (in TRANSCEND-T2D-2, by 2.2% on 9 or 12 mg against 1.8% on Ozempic 2 mg, efficacy estimand), so if tesamorelin nudged glucose up, a single A1C taken on the stack couldn't separate the two effects.

Our read: that masking is why an A1C and fasting glucose test before adding tesamorelin, and again later, tells you more than how you feel does.

The Egrifta label also asks for IGF-1 monitoring: after 26 weeks on tesamorelin, 47% of people had IGF-1 levels more than 2 standard deviations above average (an IGF-1 SDS above 2).

The skin row matters for a different reason. If you start both drugs together and your skin starts burning or tingling, you can't tell which drug is doing it. The same goes for vomiting and for a sore injection site.

What happens when you stop tesamorelin

The gains fade. In the Egrifta extension trials, people who switched from tesamorelin to placebo after 26 weeks saw their visceral fat climb back by 22% (Study 1) and 16% (Study 2) over the next 26 weeks, and they lost 1.8 kg and 1.7 kg of lean mass. People who stayed on it held steady.

Retatrutide looks similar in the little data there is: the Phase 2 liver substudy saw some weight regain at the check 4 weeks after the last dose. A stack is two drugs you'd need to keep taking, one of them every day. See retatrutide side effects for more.

Two vials, two sourcing problems

Tesamorelin has an approved, prescription route in the US. Retatrutide doesn't, anywhere, so any retatrutide sold outside Lilly's trials is unapproved (see is retatrutide legal), and a tesamorelin vial from a peptide seller isn't Egrifta either.

Victoria's health department in Australia issued an alert in June 2026 about 6 cases of acute liver injury since January in people who used products labeled as retatrutide, possibly from a contaminant. In September 2026, Australia's TGA tested a vial sold as retatrutide after a serious reaction and found no retatrutide at all, just semaglutide at about 8 times the level in approved products. With two drugs in the mix, a reaction can't be pinned on either one.

If you're considering a gray-market vial anyway, our page on retatrutide for sale covers what batch testing to ask for and the regulator cases so far, and the retatrutide vendors page explains how people check a seller's test reports. For trial doses and how retatrutide was stepped up, see the retatrutide dosage guide.

When to get medical help

Call your doctor about new swelling in your hands or feet, joint pain, or numb or tingling hands, which the Egrifta label links to fluid retention and carpal tunnel syndrome. The same goes for signs of high blood sugar, like strong thirst and peeing much more often, or blurry vision if you have diabetes. Before any surgery or procedure, tell the team about both drugs, including the one without a label.